NCT06556173View on ClinicalTrials.gov

Phase 2a Study of VTX3232 in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

April 4, 2025

Study Completion Date

April 4, 2025

Conditions
Idiopathic Parkinson Disease
Interventions
DRUG

VTX3232

Dose A

Trial Locations (1)

06510

Local Site #840001, New Haven

All Listed Sponsors
lead

Zomagen Biosciences Ltd.

INDUSTRY

NCT06556173 - Phase 2a Study of VTX3232 in Parkinson's Disease | Biotech Hunter | Biotech Hunter